Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 9 - Drugs for disorders of the cardiovascular system
Patents for A61P 9 - Drugs for disorders of the cardiovascular system (159,484)
03/2008
03/11/2008CA2179857C Medicaments for the treatment or prophylaxis of ischemia-reperfusion injury
03/06/2008WO2008027687A2 Use of tenecteplase for treating acute ischemic stroke
03/06/2008WO2008027284A1 Fused imidazole derivatives for the treatment of disorders mediated by aldosterone synthase and/or 11-beta-hydroxylase and/or aromatase
03/06/2008WO2008026965A1 Substituted pyrrolo[4,3-b]indoles, combinatorial and focused libraries, pharmacological composition and a method for the production and use thereof
03/06/2008WO2008026785A1 Lipid metabolism improving agent containing hydrogen molecule
03/06/2008WO2008026704A1 Isoquinoline derivative
03/06/2008WO2008026687A1 Pyrazolopyridine carboxamide derivative and phosphodiesterase (pde) inhibitor comprising the derivative
03/06/2008WO2008026668A1 Medicinal composition containing insulin resistance improving agent
03/06/2008WO2008026577A1 Method for producing phenoxypyridine derivative
03/06/2008WO2008026564A1 Urea derivative
03/06/2008WO2008026563A1 Hydrazine amide derivative
03/06/2008WO2008026320A1 ANTI-ANGIOGENIC AGENT, DNA SYNTHESIS INHIBITOR, p44/p42 MAPK PHOSPHORYLATION ACTIVITY INHIBITOR, AND MEDICAL KIT
03/06/2008WO2008026156A2 Therapeutic compositions comprising a specific endothelin receptor antagonist and a pde5 inhibitor
03/06/2008WO2008026149A1 1,4,5,6, 7,8-hexahydro-i^1s-triaza-azulene derivatives as orexin receptor antagonists
03/06/2008WO2008025870A1 Compositions useful especially for treatment or prevention of metabolic syndrome
03/06/2008WO2008008375A3 Triazolyl pyridyl benzenesulfonamides as ccr2 or ccr9 modulators for the treatment of inflammation
03/06/2008WO2007149873A3 Kv1.5 potassium channel inhibitors
03/06/2008WO2007143119A3 Method of preventing progression of hypertension-induced heart failure with pkc peptides
03/06/2008WO2007134867A3 Treating muscular disorders and improving muscular function
03/06/2008WO2007128761A3 Uses of dpp-iv inhibitors
03/06/2008WO2007100664A3 Modulators of muscarinic receptors
03/06/2008WO2007089688A3 Na/k-atpase ligand
03/06/2008WO2007067611A3 Methods of treating cardiac reperfusion disease
03/06/2008US20080058423 Melanin concentrating hormone antagonists
03/06/2008US20080058417 Enriched Beverages and Methods of Making The Same
03/06/2008US20080058414 Substituted Cyclopentanes Or Cyclopentanones As Therapeutic Agents
03/06/2008US20080058412 1-(4-((R,S)-5-[1,2]dithiolan-3-ylpentyloxy)-3,5-dimethylphenyl)-3-(4-carboxydimethylmethyloxy-3,5-dimethylphenyl)prop-2-en-1-one; peroxisome proliferator activated receptor agonist; lipid or glucose metabolism: hyperlipidemia, diabetes, obesity; dermatologicalal: psoriasis, atopic dermatitis, acne
03/06/2008US20080058380 2-{[2-(3,5-difluorophenyl)acetyl]amino}-N-{5-[2-(isopropoxymethyl)phenyl]-1,3-thiazol-2-yl}propanamide; neuroprotectant; neurodegenerative diseases: Alzheimer's and Parkinson's disease, Down syndrome, amyloid angiopathy and cerebrovascular disorders
03/06/2008US20080058360 Soluble CD40L (CD 154) as a prognostic marker of atherosclerotic diseases
03/06/2008US20080058354 Treating erectile dysfunction and female sexual dysfunction; side effect reduction; 1-ethyl-3-(2-hydroxyethyl)-7-(3-bromo-4-methoxyphenyl)-8-(2-hydroxycyclopenylamino)-1,2,3,6-tetrahydro-7H-purine-2,6-dione for example
03/06/2008US20080058348 Bone disorders such as osteoporosis, tumors and cardiovascular disorders; 4-(2-carboxy-2-Boc-aminoethylamino)-6-piperidinopyrimidines such as tert-butyl 2-benzyloxycarbonylamino-3-[2,5-dimethoxy-6-(4-[1,8]naphthyridin-2-yl-piperidin-1-yl)pyrimidin-4-ylamino]-propionate
03/06/2008US20080058342 potent kinase insert domain-containing receptor (KDR) inhibitors with improved selectivity and pharmacokinetics; VEGF (vascular endothelial growth factor) inhibitors; cancer and rheumatoid arthritis; e.g. 7-(2-[4-(acetylmethyl)piperazin-1-yl]ethoxy)-6-methoxy-4-[(2-methyl-1H-indol-5-yl)oxy]quinazoline
03/06/2008US20080058340 MEK kinase (mitogen-activated ERK-activating kinases or MAP kinase kinase); cancer, tumors, infections, autoimmune disorders, stroke, ischemia, rheumatoid arthritis, multiple sclerosis, psoriasis, restenosis; 1-sulfonamido-2-(phenylamino)-4-fluorobenzene compounds
03/06/2008US20080058339 4-phenyl-3-substituted pyridazine compounds such as tert-Butyl 4-[((6-[4-(methylsulfonyl)phenyl]pyridazin-3-yl)oxy)methyl]-piperidine-1-carboxylate; agonists of the G-protein-coupled receptor GPR119; diabetes and obesity; use with a dipeptidyl peptidase IV (DPP IV) inhibitor
03/06/2008US20080058335 Pain, inflammatory or immune disorders, neurological disorders, cancers of the immune system, respiratory disorders, cardiovascular disorders, neuroprotection; e.g. 5-chloro-N-[(2Z)-5-(1-hydroxy-1-methylethyl)-3-[((cis)-3-methoxycyclobutyl)methyl]-4-methyl-1,3-thiazol-2(3H)-ylidene]-2-methoxybenzamide
03/06/2008US20080058328 Substituted 4-phenyltetrahydroisoquinolines, pharmaceuitcal compositions comprising them and therapeutic methods for their use
03/06/2008US20080058325 Compounds, methods and pharmaceutical compositions for inhibiting parp
03/06/2008US20080058324 Alpha-Keto Carbonyl Calpain Inhibitors
03/06/2008US20080058323 Therapy of vascular system diseases
03/06/2008US20080058320 Organic Compounds
03/06/2008US20080058314 Novel dicarboxylic acid derivatives with pharmaceutical properties
03/06/2008US20080058311 Antagonizing N-type calcium channels; use as analgesic, neurodegenerative diseases, brain injury, bronchial asthma, unstable angina and irritable colitis, drug withdrawal symptoms; t-butyl 2-[4-(5H-dibenzo[a,d][7]annulen-5-ylidene)-1-piperidinyl]-2-oxoethylcarbamate for example
03/06/2008US20080058306 Combinations of peroxisome proliferator-activated receptor (PPAR) activator(s) and sterol absorption inhibitors(s) and treatments for vascular indications
03/06/2008US20080058293 Quinoline Derivates and Their Use in Therapy
03/06/2008US20080058270 Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
03/06/2008US20080058263 Polypeptides that binds to cellular receptors; animal growth regukators
03/06/2008US20080058252 Use of C5A receptor antagonist in the treatment of fibrosis
03/06/2008US20080057515 Beta-like glycoprotein hormone polypeptide and heterodimer
03/06/2008US20080057123 Tablet core has the drug and an enteric material and is surrounded by one or more barrier layers of swellable, erodible, or gellable polymers; release rate increases in resopnse to increasing pH as the tablet descends the gastrointestinal tract; once daily dosing
03/06/2008US20080057103 Methods of using medical devices for controlled drug release
03/06/2008US20080057069 Method of increasing trafficking of endothelial progenitor cells to ischemia-damaged tissue
03/06/2008US20080057043 human and mouse monocyte cells expressing angiopoietin receptors and CD14/antigen markers, used for regulating neovascularization
03/06/2008US20080057026 Amphiphilic Star-Like Or Scorpion-Like Macromolecules, Various Compositions And Uses Threof
03/06/2008US20080056993 Post-ischemic myocardial injury; administer a first concurrent parenteral infusion of adenosine and inosine during or following an acute myocardial infarction; protect against reperfusion following ischemic insult in the heart, brain, spinal cord, anti-inflammatory, reduce pain, anesthesia requirements
03/06/2008US20080056987 Inhibitor of Eph receptor kinase; treat angiogenesis, lymphangiogenesis or asculogenesis, disorder of the blood vessels, hyperproliferation of body cells, chronic or acute neurodegenerative disorder; enteral, parenteral and oral administration
03/06/2008CA2667330A1 Lipid metabolism improving agent containing hydrogen molecules
03/06/2008CA2661850A1 Pyrazolopyridine carboxamide derivative and phosphodiesterase (pde) inhibitor containing the same
03/06/2008CA2661702A1 Method for producing phenoxypyridine derivative
03/06/2008CA2661012A1 Method of treating stroke with thrombolytic agent
03/06/2008CA2660701A1 Fused imidazole derivatives for the treatment of disorders mediated by aldosterone synthase and/or 11-beta-hydroxylase and/or aromatase
03/06/2008CA2659770A1 Therapeutic compositions comprising a specific endothelin receptor antagonist and a pde5 inhibitor
03/06/2008CA2659352A1 1,4,5,6,7,8-hexahydro-1,2,5-triaza-azulene derivatives as orexin receptor antagonists
03/05/2008EP1895005A1 Cell-permeable peptide inhibitors of the JNK signal transduction pathway
03/05/2008EP1894997A1 Improvement of cardiac function by mesenchymal stem cell transplantation
03/05/2008EP1894930A1 Thiazole derivative
03/05/2008EP1894919A1 Heterocyclic compound having type i 11 beta hydroxysteroid dehydrogenase inhibitory activity
03/05/2008EP1894582A1 Method for control of drug elution rate and composition for coating of drug-eluting stent
03/05/2008EP1894576A1 Novel triglyceride reducing agent
03/05/2008EP1894570A2 Methods and compositions for the treatment of peripheral artery disease
03/05/2008EP1894567A1 Concomitant pharmaceutical agents and use thereof
03/05/2008EP1894566A1 Products containing polyphenol(s) and L-arginine to stimulate nitric oxide production
03/05/2008EP1893750A1 Amniotic cells and methods for use thereof
03/05/2008EP1893634A2 Pyrimidine derivatives and their use as p2y12 receptor antagonists
03/05/2008EP1893619A1 New oxabispidine compounds for the treatment of cardiac arrhytmias
03/05/2008EP1893609A1 N-(pyridin-2-yl)-sulfonamide derivatives
03/05/2008EP1893580A1 NOVEL SALT FORM OF A ß2 -ADRENERGIC AGONIST QUINOLIN-2-ONE DERIVATIVE
03/05/2008EP1893578A2 Novel piperidine carboxylic acid amide derivatives
03/05/2008EP1893222A2 Anti-hypercholesterolemic compounds
03/05/2008EP1893219A2 Use of spirostenols to treat mitochondrial disorders
03/05/2008EP1893203A2 Medicament containing a betamimetic in conjunction with an anticholinergic and a pde iv inhibitor
03/05/2008EP1893199A2 Pdz-domain modulators
03/05/2008EP1713797B1 1-isopropyl-2-oxo-1,2-dihydropyridine-3-carboxamide derivatives having 5-ht4 receptor agonistic activity
03/05/2008EP1661913B1 Bioactive peptides derived from the proteins of egg white by means of enzymatic hydrolysis
03/05/2008EP1411919B1 (-)-olivil as antioxidant
03/05/2008EP1383733B1 Process for the preparation of 1,3-substituted indenes and aryl-fused azapolycyclic compounds
03/05/2008EP1070253B1 USE OF hRORalpha RECEPTORS FOR SCREENING SUBSTANCES USEFUL FOR THE TREATMENT OF ATHEROSCLEROSIS
03/05/2008EP0989993B1 Tartrate salt of a substituted dipeptide as growth hormone secretagogue
03/05/2008CN101137650A 2-[(isoquinolin-3-carbonyl)amino]-propionic acid derivatives as inhibitors of factors xi and ix for the treatment of thrombosis
03/05/2008CN101137639A Flavonoid compounds and uses thereof
03/05/2008CN101137629A Non-anilinic derivatives of isothiazol-3(2h)-thione 1,1-dioxides as liver x receptor modulators
03/05/2008CN101137625A Cinnamate salts of a beta-2 adrenergic agonist
03/05/2008CN101137396A Production of bioactive glycoproteins from inactive starting material
03/05/2008CN101137390A Novel angiogensis inhibitor
03/05/2008CN101137387A Pharmaceutical composition and method for neoangiogenesis/revascularization useful in treating ischemic heart diseases
03/05/2008CN101137367A Benazapril and amlodipine besylate for reducing cardiovascular morbidity
03/05/2008CN101137366A Compounds for treating autoimmune and demyelinating diseases
03/05/2008CN101137361A Potassium channel opener having benzofuroindole skeleton
03/05/2008CN101134953A Recombinant human pancreas kininogenase
03/05/2008CN101134764A Method for synthesizing target compound-ligustrazine derivant preventing cerebrovascular disease
03/05/2008CN101134745A Nitric oxide donator type telmisartan derivant, preparation method and medical uses thereof
1 ... 560 561 562 563 564 565 566 567 568 569 570 571 572 573 574 575 576 577 578 579 580 ... 1595